WO2003001182A2 - Transthyretine homocysteinylee - Google Patents
Transthyretine homocysteinylee Download PDFInfo
- Publication number
- WO2003001182A2 WO2003001182A2 PCT/US2002/019928 US0219928W WO03001182A2 WO 2003001182 A2 WO2003001182 A2 WO 2003001182A2 US 0219928 W US0219928 W US 0219928W WO 03001182 A2 WO03001182 A2 WO 03001182A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- homocysteine
- ttr
- fibronectin
- hcy
- sample
- Prior art date
Links
- 108010071690 Prealbumin Proteins 0.000 title claims abstract description 28
- 102000009190 Transthyretin Human genes 0.000 title claims abstract description 28
- FFFHZYDWPBMWHY-VKHMYHEASA-N L-homocysteine Chemical compound OC(=O)[C@@H](N)CCS FFFHZYDWPBMWHY-VKHMYHEASA-N 0.000 claims abstract description 113
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 66
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 66
- 238000000034 method Methods 0.000 claims abstract description 61
- 208000033892 Hyperhomocysteinemia Diseases 0.000 claims abstract description 18
- 239000000203 mixture Substances 0.000 claims abstract description 12
- 102000016359 Fibronectins Human genes 0.000 claims description 99
- 108010067306 Fibronectins Proteins 0.000 claims description 99
- 239000000523 sample Substances 0.000 claims description 35
- 238000003556 assay Methods 0.000 claims description 31
- 210000002966 serum Anatomy 0.000 claims description 21
- 239000012472 biological sample Substances 0.000 claims description 17
- 238000003018 immunoassay Methods 0.000 claims description 17
- 102000009027 Albumins Human genes 0.000 claims description 16
- 108010088751 Albumins Proteins 0.000 claims description 16
- 238000001114 immunoprecipitation Methods 0.000 claims description 9
- 238000001514 detection method Methods 0.000 abstract description 16
- 230000003225 hyperhomocysteinemia Effects 0.000 abstract description 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 10
- 201000010099 disease Diseases 0.000 abstract description 9
- 239000013060 biological fluid Substances 0.000 abstract description 7
- 238000003745 diagnosis Methods 0.000 abstract description 7
- 239000003550 marker Substances 0.000 abstract description 5
- 238000002955 isolation Methods 0.000 abstract description 4
- 210000002381 plasma Anatomy 0.000 description 63
- 235000018102 proteins Nutrition 0.000 description 53
- 102000009123 Fibrin Human genes 0.000 description 32
- 108010073385 Fibrin Proteins 0.000 description 32
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 32
- 229950003499 fibrin Drugs 0.000 description 32
- 108090000765 processed proteins & peptides Proteins 0.000 description 29
- FFFHZYDWPBMWHY-UHFFFAOYSA-N L-Homocysteine Natural products OC(=O)C(N)CCS FFFHZYDWPBMWHY-UHFFFAOYSA-N 0.000 description 28
- 102000004196 processed proteins & peptides Human genes 0.000 description 26
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 21
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 18
- 239000000499 gel Substances 0.000 description 18
- 238000004128 high performance liquid chromatography Methods 0.000 description 14
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 13
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 12
- 238000002965 ELISA Methods 0.000 description 11
- 238000001727 in vivo Methods 0.000 description 11
- 102000004190 Enzymes Human genes 0.000 description 10
- 108090000790 Enzymes Proteins 0.000 description 10
- JOCBASBOOFNAJA-UHFFFAOYSA-N N-tris(hydroxymethyl)methyl-2-aminoethanesulfonic acid Chemical compound OCC(CO)(CO)NCCS(O)(=O)=O JOCBASBOOFNAJA-UHFFFAOYSA-N 0.000 description 10
- 238000004458 analytical method Methods 0.000 description 10
- 229940088598 enzyme Drugs 0.000 description 10
- 230000002285 radioactive effect Effects 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- 230000029663 wound healing Effects 0.000 description 10
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 9
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 239000007994 TES buffer Substances 0.000 description 9
- 238000001819 mass spectrum Methods 0.000 description 9
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 229940098773 bovine serum albumin Drugs 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 8
- 231100000673 dose–response relationship Toxicity 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 8
- 230000002829 reductive effect Effects 0.000 description 8
- 238000000926 separation method Methods 0.000 description 8
- 102000004506 Blood Proteins Human genes 0.000 description 7
- 108010017384 Blood Proteins Proteins 0.000 description 7
- 108010010803 Gelatin Proteins 0.000 description 7
- 150000001413 amino acids Chemical class 0.000 description 7
- 239000000427 antigen Substances 0.000 description 7
- 108091007433 antigens Proteins 0.000 description 7
- 102000036639 antigens Human genes 0.000 description 7
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 7
- 235000018417 cysteine Nutrition 0.000 description 7
- 230000029087 digestion Effects 0.000 description 7
- 239000008273 gelatin Substances 0.000 description 7
- 229920000159 gelatin Polymers 0.000 description 7
- 235000019322 gelatine Nutrition 0.000 description 7
- 235000011852 gelatine desserts Nutrition 0.000 description 7
- 238000000338 in vitro Methods 0.000 description 7
- 230000003993 interaction Effects 0.000 description 7
- 239000007983 Tris buffer Substances 0.000 description 6
- 108090000631 Trypsin Proteins 0.000 description 6
- 102000004142 Trypsin Human genes 0.000 description 6
- 235000001014 amino acid Nutrition 0.000 description 6
- YPHMISFOHDHNIV-FSZOTQKASA-N cycloheximide Chemical compound C1[C@@H](C)C[C@H](C)C(=O)[C@@H]1[C@H](O)CC1CC(=O)NC(=O)C1 YPHMISFOHDHNIV-FSZOTQKASA-N 0.000 description 6
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 6
- 230000009467 reduction Effects 0.000 description 6
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 6
- 239000012588 trypsin Substances 0.000 description 6
- 101000772194 Homo sapiens Transthyretin Proteins 0.000 description 5
- 239000004201 L-cysteine Substances 0.000 description 5
- 210000004899 c-terminal region Anatomy 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 239000012634 fragment Substances 0.000 description 5
- 102000056556 human TTR Human genes 0.000 description 5
- 238000011534 incubation Methods 0.000 description 5
- 150000002500 ions Chemical class 0.000 description 5
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 5
- 229960004452 methionine Drugs 0.000 description 5
- 238000003322 phosphorimaging Methods 0.000 description 5
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 5
- 238000001262 western blot Methods 0.000 description 5
- QFVHZQCOUORWEI-UHFFFAOYSA-N 4-[(4-anilino-5-sulfonaphthalen-1-yl)diazenyl]-5-hydroxynaphthalene-2,7-disulfonic acid Chemical compound C=12C(O)=CC(S(O)(=O)=O)=CC2=CC(S(O)(=O)=O)=CC=1N=NC(C1=CC=CC(=C11)S(O)(=O)=O)=CC=C1NC1=CC=CC=C1 QFVHZQCOUORWEI-UHFFFAOYSA-N 0.000 description 4
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 4
- 208000024172 Cardiovascular disease Diseases 0.000 description 4
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 4
- 206010020365 Homocystinuria Diseases 0.000 description 4
- 235000013878 L-cysteine Nutrition 0.000 description 4
- 206010052428 Wound Diseases 0.000 description 4
- 208000027418 Wounds and injury Diseases 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 208000020832 chronic kidney disease Diseases 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 4
- 230000034994 death Effects 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 238000002290 gas chromatography-mass spectrometry Methods 0.000 description 4
- 229960003180 glutathione Drugs 0.000 description 4
- KIWQWJKWBHZMDT-UHFFFAOYSA-N homocysteine thiolactone Chemical compound NC1CCSC1=O KIWQWJKWBHZMDT-UHFFFAOYSA-N 0.000 description 4
- 238000002372 labelling Methods 0.000 description 4
- 238000004949 mass spectrometry Methods 0.000 description 4
- 239000011159 matrix material Substances 0.000 description 4
- 239000008188 pellet Substances 0.000 description 4
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 4
- 230000002035 prolonged effect Effects 0.000 description 4
- 238000000159 protein binding assay Methods 0.000 description 4
- 238000003127 radioimmunoassay Methods 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 239000007790 solid phase Substances 0.000 description 4
- 238000004885 tandem mass spectrometry Methods 0.000 description 4
- 150000003573 thiols Chemical class 0.000 description 4
- 239000003656 tris buffered saline Substances 0.000 description 4
- 241000283707 Capra Species 0.000 description 3
- 108010024636 Glutathione Proteins 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- ZUKPVRWZDMRIEO-VKHMYHEASA-N L-cysteinylglycine Chemical compound SC[C@H]([NH3+])C(=O)NCC([O-])=O ZUKPVRWZDMRIEO-VKHMYHEASA-N 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- LSNNMFCWUKXFEE-UHFFFAOYSA-N Sulfurous acid Chemical compound OS(O)=O LSNNMFCWUKXFEE-UHFFFAOYSA-N 0.000 description 3
- 210000001124 body fluid Anatomy 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 238000003759 clinical diagnosis Methods 0.000 description 3
- 108010016616 cysteinylglycine Proteins 0.000 description 3
- 230000007812 deficiency Effects 0.000 description 3
- 238000002875 fluorescence polarization Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 238000013508 migration Methods 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 208000015380 nutritional deficiency disease Diseases 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 239000012723 sample buffer Substances 0.000 description 3
- 239000012679 serum free medium Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- TUSDEZXZIZRFGC-UHFFFAOYSA-N 1-O-galloyl-3,6-(R)-HHDP-beta-D-glucose Natural products OC1C(O2)COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC1C(O)C2OC(=O)C1=CC(O)=C(O)C(O)=C1 TUSDEZXZIZRFGC-UHFFFAOYSA-N 0.000 description 2
- 238000009007 Diagnostic Kit Methods 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 239000001263 FEMA 3042 Substances 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- KIWQWJKWBHZMDT-VKHMYHEASA-N L-homocysteine thiolactone Chemical compound N[C@H]1CCSC1=O KIWQWJKWBHZMDT-VKHMYHEASA-N 0.000 description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
- LRBQNJMCXXYXIU-PPKXGCFTSA-N Penta-digallate-beta-D-glucose Natural products OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-PPKXGCFTSA-N 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 229920002684 Sepharose Polymers 0.000 description 2
- 206010042434 Sudden death Diseases 0.000 description 2
- 208000007536 Thrombosis Diseases 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 238000001042 affinity chromatography Methods 0.000 description 2
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 2
- 238000002399 angioplasty Methods 0.000 description 2
- 229910052786 argon Inorganic materials 0.000 description 2
- 238000005415 bioluminescence Methods 0.000 description 2
- 230000029918 bioluminescence Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- 230000007211 cardiovascular event Effects 0.000 description 2
- 238000003352 cell adhesion assay Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000003593 chromogenic compound Substances 0.000 description 2
- 208000022831 chronic renal failure syndrome Diseases 0.000 description 2
- 230000035602 clotting Effects 0.000 description 2
- 239000000356 contaminant Substances 0.000 description 2
- 239000012502 diagnostic product Substances 0.000 description 2
- 239000000539 dimer Substances 0.000 description 2
- 125000002228 disulfide group Chemical group 0.000 description 2
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 2
- 230000002526 effect on cardiovascular system Effects 0.000 description 2
- 238000000835 electrochemical detection Methods 0.000 description 2
- 208000028208 end stage renal disease Diseases 0.000 description 2
- 201000000523 end stage renal failure Diseases 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 238000001917 fluorescence detection Methods 0.000 description 2
- 239000007850 fluorescent dye Substances 0.000 description 2
- 239000011544 gradient gel Substances 0.000 description 2
- 230000003100 immobilizing effect Effects 0.000 description 2
- 239000012133 immunoprecipitate Substances 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 229930182817 methionine Natural products 0.000 description 2
- 230000005012 migration Effects 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 230000001376 precipitating effect Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000004393 prognosis Methods 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 229920002258 tannic acid Polymers 0.000 description 2
- LRBQNJMCXXYXIU-NRMVVENXSA-N tannic acid Chemical compound OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-NRMVVENXSA-N 0.000 description 2
- 229940033123 tannic acid Drugs 0.000 description 2
- 235000015523 tannic acid Nutrition 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 2
- 238000000539 two dimensional gel electrophoresis Methods 0.000 description 2
- 238000012800 visualization Methods 0.000 description 2
- GEYOCULIXLDCMW-UHFFFAOYSA-N 1,2-phenylenediamine Chemical compound NC1=CC=CC=C1N GEYOCULIXLDCMW-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- KIUMMUBSPKGMOY-UHFFFAOYSA-N 3,3'-Dithiobis(6-nitrobenzoic acid) Chemical compound C1=C([N+]([O-])=O)C(C(=O)O)=CC(SSC=2C=C(C(=CC=2)[N+]([O-])=O)C(O)=O)=C1 KIUMMUBSPKGMOY-UHFFFAOYSA-N 0.000 description 1
- XMTQQYYKAHVGBJ-UHFFFAOYSA-N 3-(3,4-DICHLOROPHENYL)-1,1-DIMETHYLUREA Chemical compound CN(C)C(=O)NC1=CC=C(Cl)C(Cl)=C1 XMTQQYYKAHVGBJ-UHFFFAOYSA-N 0.000 description 1
- OROGUZVNAFJPHA-UHFFFAOYSA-N 3-hydroxy-2,4-dimethyl-2H-thiophen-5-one Chemical compound CC1SC(=O)C(C)=C1O OROGUZVNAFJPHA-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- 108010000239 Aequorin Proteins 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 206010002388 Angina unstable Diseases 0.000 description 1
- 108010039627 Aprotinin Proteins 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 208000037260 Atherosclerotic Plaque Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 238000009010 Bradford assay Methods 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 206010053567 Coagulopathies Diseases 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- IGXWBGJHJZYPQS-SSDOTTSWSA-N D-Luciferin Chemical compound OC(=O)[C@H]1CSC(C=2SC3=CC=C(O)C=C3N=2)=N1 IGXWBGJHJZYPQS-SSDOTTSWSA-N 0.000 description 1
- CYCGRDQQIOGCKX-UHFFFAOYSA-N Dehydro-luciferin Natural products OC(=O)C1=CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 CYCGRDQQIOGCKX-UHFFFAOYSA-N 0.000 description 1
- 206010063560 Excessive granulation tissue Diseases 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 208000001362 Fetal Growth Retardation Diseases 0.000 description 1
- 108010049003 Fibrinogen Proteins 0.000 description 1
- 102000008946 Fibrinogen Human genes 0.000 description 1
- BJGNCJDXODQBOB-UHFFFAOYSA-N Fivefly Luciferin Natural products OC(=O)C1CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 BJGNCJDXODQBOB-UHFFFAOYSA-N 0.000 description 1
- 206010070531 Foetal growth restriction Diseases 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- FFEARJCKVFRZRR-UHFFFAOYSA-N L-Methionine Natural products CSCCC(N)C(O)=O FFEARJCKVFRZRR-UHFFFAOYSA-N 0.000 description 1
- 229930195722 L-methionine Natural products 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- DDWFXDSYGUXRAY-UHFFFAOYSA-N Luciferin Natural products CCc1c(C)c(CC2NC(=O)C(=C2C=C)C)[nH]c1Cc3[nH]c4C(=C5/NC(CC(=O)O)C(C)C5CC(=O)O)CC(=O)c4c3C DDWFXDSYGUXRAY-UHFFFAOYSA-N 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 108010004729 Phycoerythrin Proteins 0.000 description 1
- 238000010847 SEQUEST Methods 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- 206010049418 Sudden Cardiac Death Diseases 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 108090000190 Thrombin Proteins 0.000 description 1
- 102000004338 Transferrin Human genes 0.000 description 1
- 108090000901 Transferrin Proteins 0.000 description 1
- 208000007814 Unstable Angina Diseases 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 238000003916 acid precipitation Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 238000007818 agglutination assay Methods 0.000 description 1
- 150000004347 all-trans-retinol derivatives Chemical class 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 239000000959 ampholyte mixture Substances 0.000 description 1
- 108010082290 angiotensinogen (1-14) Proteins 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000001857 anti-mycotic effect Effects 0.000 description 1
- 239000002543 antimycotic Substances 0.000 description 1
- 210000003433 aortic smooth muscle cell Anatomy 0.000 description 1
- 229960004405 aprotinin Drugs 0.000 description 1
- 230000003143 atherosclerotic effect Effects 0.000 description 1
- 238000000376 autoradiography Methods 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- UDSAIICHUKSCKT-UHFFFAOYSA-N bromophenol blue Chemical compound C1=C(Br)C(O)=C(Br)C=C1C1(C=2C=C(Br)C(O)=C(Br)C=2)C2=CC=CC=C2S(=O)(=O)O1 UDSAIICHUKSCKT-UHFFFAOYSA-N 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 208000010877 cognitive disease Diseases 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 238000004737 colorimetric analysis Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000008482 dysregulation Effects 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 238000011067 equilibration Methods 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 208000030941 fetal growth restriction Diseases 0.000 description 1
- 229940012952 fibrinogen Drugs 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- ZFKJVJIDPQDDFY-UHFFFAOYSA-N fluorescamine Chemical compound C12=CC=CC=C2C(=O)OC1(C1=O)OC=C1C1=CC=CC=C1 ZFKJVJIDPQDDFY-UHFFFAOYSA-N 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 238000001215 fluorescent labelling Methods 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- AOQKTXNIXJZEJT-UHFFFAOYSA-N formic acid;methanol;hydrate Chemical compound O.OC.OC=O AOQKTXNIXJZEJT-UHFFFAOYSA-N 0.000 description 1
- 238000012817 gel-diffusion technique Methods 0.000 description 1
- 210000001126 granulation tissue Anatomy 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 229940106780 human fibrinogen Drugs 0.000 description 1
- 235000003642 hunger Nutrition 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- XJFQCYIFOWHHFN-PLKCGDGVSA-N hypertensinogen Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C1=CC=C(O)C=C1 XJFQCYIFOWHHFN-PLKCGDGVSA-N 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 230000000951 immunodiffusion Effects 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 201000004332 intermediate coronary syndrome Diseases 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- PGLTVOMIXTUURA-UHFFFAOYSA-N iodoacetamide Chemical compound NC(=O)CI PGLTVOMIXTUURA-UHFFFAOYSA-N 0.000 description 1
- 238000005040 ion trap Methods 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 238000001155 isoelectric focusing Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- 230000001071 malnutrition Effects 0.000 description 1
- 235000000824 malnutrition Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 230000002906 microbiologic effect Effects 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 238000000329 molecular dynamics simulation Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- AHEWZZJEDQVLOP-UHFFFAOYSA-N monobromobimane Chemical compound BrCC1=C(C)C(=O)N2N1C(C)=C(C)C2=O AHEWZZJEDQVLOP-UHFFFAOYSA-N 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 210000004897 n-terminal region Anatomy 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 238000004816 paper chromatography Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 230000009805 platelet accumulation Effects 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 238000000163 radioactive labelling Methods 0.000 description 1
- 239000002287 radioligand Substances 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000007430 reference method Methods 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 208000037803 restenosis Diseases 0.000 description 1
- 229960003471 retinol Drugs 0.000 description 1
- 235000020944 retinol Nutrition 0.000 description 1
- 239000011607 retinol Substances 0.000 description 1
- 102000029752 retinol binding Human genes 0.000 description 1
- 108091000053 retinol binding Proteins 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 238000003345 scintillation counting Methods 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000011877 solvent mixture Substances 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 230000037351 starvation Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 229960004072 thrombin Drugs 0.000 description 1
- 230000002885 thrombogenetic effect Effects 0.000 description 1
- 208000037816 tissue injury Diseases 0.000 description 1
- 230000007838 tissue remodeling Effects 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 239000012581 transferrin Substances 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 210000004509 vascular smooth muscle cell Anatomy 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 230000037314 wound repair Effects 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
- G01N33/6806—Determination of free amino acids
- G01N33/6812—Assays for specific amino acids
- G01N33/6815—Assays for specific amino acids containing sulfur, e.g. cysteine, cystine, methionine, homocysteine
Definitions
- Elevated levels of the amino acid homocysteine (Hey) in plasma and tissue extracts is associated with and/or related to many serious pathological conditions.
- Homocysteine is a strong independent risk factor of cardiovascular disease
- an elevated blood level of Hey i.e., hyperhomocysteinemia or homocystinuria
- Elevated levels of Hey are even more pronounced with other compromised organ or medical conditions, including cardiovascular and neurological ailments, for example, heart and kidney transplants, end-stage renal disease, Alzheimer's disease, diabetes, and preclampsia and fetal growth restriction.
- Hyperhomocysteinemia is a strong independent risk factor for coronary artery disease, cerebrovascular disease, and peripheral vascular occlusive disease. The prognosis for patients with cardiovascular disease (and other diseases as well) combined with high levels of plasma total homocysteine (tHcy) is poor. Recent studies suggest that hyperhomocysteinemia is also a risk factor for other disorders of cognitive dysfunction.
- tHcy There are several assays for the determination of tHcy.
- the existing assays for tHcy include both research and commercial technologies.
- Current methodologies include HPLC with fluorescence detection, HPLC with electrochemical detection, gas chromatography-mass spectroscopy (GC/MS), tandem mass spectroscopy, fluorescence polarization immunoassay (Abbott Laboratories IMx platform), ELISA (Bio-Rad), chemiluminescence (Diagnostic Products Corporation) and others, as have been previously disclosed and are apparent to those skilled in the art.
- An embodiment of the present invention provides a composition comprised of homocysteine and a mammalian protein covalently attached in a purified and isolated form.
- the composition of homocysteine and mammalian protein may be covalently attached by a disulfide bond.
- the mammalian protein may be selected from the group consisting of albumin, fibronectin, and transthyretin. If the mammalian protein is transthyretin, then Cys 10 is involved in forming the disulfide bond.
- Another embodiment of the present invention provides a method of determining levels of Hey in a sample comprising detecting levels of a mammalian protein.
- the mammalian protein may be selected from the group consisting of albumin, fibronectin, and transthyretin.
- the levels of Hey may be indicative of Hey in the sample.
- the sample may be a biological sample.
- Another embodiment of the present invention provides a method of identifying a diseased state comprised of determining the levels of homocysteine in a biological sample from a subject by determining the levels of homocysteinylated mammalian protein in the biological sample.
- the homocysteinylated mammalian protein may be selected from the group consisting of albumin, fibronectin, and transthyretin.
- the homocysteinylated transthyretin may be detected using an immunoassay.
- the immunoassay may be an immunoprecipitation assay.
- the sample may be a serum sample.
- the diseased state may be homocysteinemia.
- an isolated homocysteinylated protein is provided and serves as an indicator of elevated levels of homocysteine and diseased states associated therewith.
- the homocysteinylated proteins include albumin, fibronectin, and transthyretin.
- a novel homocysteinylated transthyretin (Hcy-TTR) complex is provided.
- Transthyretin (“TTR”) is a 13.8 kDa polypeptide that forms homodimers and homotetramers in circulation.
- Tetrameric TTR combines with retinol-saturated retinol binding protein for delivery of retinol to cells throughout the body.
- Tetrameric TTR also carries thyroxin, in circulation.
- Plasma TTR is a 127 amino acid protein containing a single cysteine residue at position 10. The protein is synthesized in the liver in a constitutive manner, and in circulation exists as a homotetramer.
- TTR forms a complex with homocysteine in a dose-dependent manner based on the concentration of plasma tHcy. It is also disclosed that certain other proteins, e.g. fibronectin and albumin, also have a dose-dependent relationship to homeocysteine plasma levels.
- fibronectin and albumin also have a dose-dependent relationship to homeocysteine plasma levels.
- Hcy-TTR For convenience, specific reference is made to Hcy-TTR throughout the specification, but it is to be noted that other plasma proteins (e.g., albumin and fibronectin) may find utility in the embodiments described herein.
- IP immunoprecipitation
- HPLC high-performance liquid chromatography
- EIMS electrospray ionization mass spectroscopy
- Hcy- TTR homocysteinylated-TTR
- Another embodiment of the present invention provides for a method of detecting the levels of homocysteine present in plasma, serum or other biological sample taken from a subject.
- the method of detecting Hey levels is accomplished by measuring the level of Hcy-TTR in the sample, with such measurement being indicative of the Hey level present in the sample.
- Another embodiment of the present invention provides for the method of identifying a subject's diseased state by measuring the level of homocysteine present in a subject's plasma, serum or other biological sample.
- the level of homocysteine is determined by measuring the level of Hcy-TTR or other homocysteinylated protein present in the sample.
- the level of Hcy- TTR is measured using an immunoassay, such as an immunoprecipitation assay.
- Yet another embodiment of the present invention provides for a method of diagnosis of homocysteinemia.
- a sample of plasma, serum or other biological sample is contacted with a sample containing transthyretin under conditions such that a specific antigen-antibody binding can occur.
- the contacting of transthyretin with a subject's sample creates a Hcy-TTR complex.
- Detection of immunospecific binding of autoantibodies to the Hcy-TTR complex indicates the degree that homocysteine is present in the subject's sample.
- Detection of the autoantibodies includes the use of a signal-generating component bound to an antibody that is specific for the antibodies in the subject's sample.
- the presence of autoantibodies in the subject's sample is measured by an immunoassay, which includes the steps of immobilizing homocysteine onto a membrane, contacting the membrane with transthyretin and detecting the presence of autoantibodies specific for the resulting Hcy-TTR complex.
- the presence of autoantibodies to the Hcy-TTR complex indicates the degree to which homocysteine is present in the subject's sample.
- kits which will be conveniently used in clinical settings, to diagnose or monitor the level of homocysteine in a subject by detecting the level of homocysteine (e.g., via Hcy-TTR) in the subject's serum, plasma or biological sample.
- the component for detecting Hcy-TTR is an anti- Hcy-TTR antibody, with the anti-Hcy-TTR antibody is labeled.
- the label is a radioactive, fluorescent, colorimetric or enzyme label.
- the kit additionally may have a labeled second antibody that immunospecifically binds to the anti-Hcy-TTR antibody.
- kits for diagnosis and prognosis of homocysteine levels in a subject which includes a component for detecting the presence of Hcy-TTR autoantibodies in a subject's sample.
- the component that is used for detection is an Hcy-TTR antigen that is labeled.
- the Hcy-TTR antigen is linked to a solid phase.
- the component is also used to detect the Hcy-TTR autoantibody.
- Figure 1 illustrates in vivo labeling of human plasma (lane 1) and commercially available purified human TTR (lane 2) with 35 S-L-homocysteine followed by resolution of labeled protein using SDS-PAGE.
- Lane 1 shows 35 S-TTR (tetramer), albumin, and TTR (dimer) and other higher molecular weight proteins.
- Lane 2 shows 35 S-labeled TTR; predominantly the dimeric form in a purified commercial preparation.
- Figure 2 illustrates the mass spectrum for the in vitro dose-dependent study for concentration of ⁇ M L-homocysteine
- Figure 3 A illustrates the mass spectrum for the in vitro dose-dependent study for concentration of 250 ⁇ M L-homocysteine with the charge envelope of intact TTR (16+ charge state is shown as inset);
- FIG. 3B illustrates the mass spectrum of the deconvolved mass of intact TTR
- Figure 4 illustrates in vitro ratio peak intensities (deconvolved) ratios of homocysteinylated TTR (atomic mass of 13,895) to S-Cysteinylated TTR (S-Cys) (Atomic Mass of 13,881).
- Figure 5 A illustrates the mass spectrum of the charge envelope for intact protein for the in vivo concentration of 20.7 ⁇ M L-homocysteine by the clinical method TTR (16+ charge state is shown as inset);
- Figure 5B illustrates the mass spectrum deconvolved for the in vivo concentration of 20.7 ⁇ M L-homocysteine by the clinical method
- Figure 6 A illustrates the mass spectrum of the charge envelope for intact protein for the in vivo concentration of 434 ⁇ M L-homocysteine by the clinical method TTR (16+ charge state is shown as inset);
- Figure 6B illustrates the mass spectrum deconvolved for the in vivo concentration of 434 ⁇ M L-homocysteine by the clinical method
- Figure 7 illustrates the in vivo ratio peak intensities (deconvolved) of S-HomoCys to Scys TTR.
- sample it is meant a volume of fluid or tissue, such as serum, and other bodily fluids, but particularly plasma which is obtained at one point in time.
- the analyses should be carried out within some short time frame after the sample is taken, as at room temperature Hey concentrations tend to increase over time due to the protracted production and release of Hey by blood cells. This process is slowed down when the blood samples are left on ice. While the description particularly identifies TTR, the methods may be used to determine the identity of other plasma proteins, such as fibronectin, that may bind to homocysteine.
- Hcy-TTR homocysteinylated proteins
- Assays for the determination of tHcy are known in the art.
- the existing assays for tHcy include both research and commercial technologies.
- Current methodologies include HPLC with fluorescence detection, HPLC with electrochemical detection, gas chromatography-mass spectroscopy (GC/MS), tandem mass spectroscopy, fluorescence polarization immunoassay (Abbott Laboratories IMx platform), ELISA (Bio-Rad), chemiluminescence (Diagnostic Products Corporation) and others.
- GC/MS gas chromatography-mass spectroscopy
- ELISA Bio-Rad
- chemiluminescence Diagnostic Products Corporation
- Immunoassays to be used in the practice of the invention include but are not limited to assay systems using techniques such as Western blots, radioimmunoassays, ELISA (enzyme linked immunosorbent assay),"sandwich” immunoassays, immunoprecipitation assays, precipitin reactions, gel diffusion precipitin reactions, immunodiffusion assays, agglutination assays, complement fixation assays, immunoradiometric assays, fluorescent immunoassays, protein A immunoassays, to name but a few.
- assay systems using techniques such as Western blots, radioimmunoassays, ELISA (enzyme linked immunosorbent assay),"sandwich” immunoassays, immunoprecipitation assays, precipitin reactions, gel diffusion precipitin reactions, immunodiffusion assays, agglutination assays, complement fixation assays, immunoradiometric assays, fluorescent immunoassays,
- a biological sample which may contain Hcy-TTR such as serum or other biological fluids, is obtained from a subject.
- Immunoassays for detecting expression of Hcy-TTR typically comprise contacting the biological sample, such as a serum sample derived from a subject, with a monoclonal anti-Hcy-TTR antibody under conditions such that specific antigen-antibody binding can occur, and detecting or measuring the amount of any immunospecific binding by the antibody.
- binding of antibody for example, can be used to detect the presence and increased expression of Hcy-TTR wherein the detection of increased expression of Hcy-TTR is an indication of a diseased condition.
- the levels of Hcy-TTR in a serum sample are compared to norms that have been established.
- the antibody such as a monoclonal antibody, according to the present invention can be produced by immunizing animals with, as an immunogen (e.g., human Hcy-TTR) obtained according to the present invention based on techniques known or widely applicable in the art. Examples of such techniques are found in Milstein et al., Nature, 256: 495 to 497, 1975, etc., the disclosures of which are hereby incorporated by reference.
- an immunogen e.g., human Hcy-TTR
- the biological sample such as a serum sample is brought in contact with a solid phase support or carrier, such as nitrocellulose, for the purpose of immobilizing any Hcy-TTR complex present in the sample.
- a solid phase support or carrier such as nitrocellulose
- the support is then washed with suitable buffers followed by treatment with detectably labeled Hcy-TTR specific antibody.
- the solid phase support is then washed with the buffer a second time to remove unbound antibody.
- the amount of bound antibody on the solid support is then determined according to well known methods. Those skilled in the art will be able to determine optional assay conditions for each determination by employing routine experimentation.
- Hcy-TTR antibodies can be detectably labeled is by linking the antibody to an enzyme, such as for use in an enzyme immunoassay (EIA) (Voller, A., "The Enzyme Linked Immunosorbent Assay (ELISA)", 1978, Diagnostic Horizons 2: 1-7, Microbiological Associates Quarterly Publication, Walkersville, MD; Voller, A., et al., 1978, J. Clin. Pathol. 31: 507-520; Butler, J. E., 1981, Meth. Enzymol. 73: 482-523).
- EIA enzyme immunoassay
- the enzyme which is bound to the antibody will react with an appropriate substrate, preferably a chromogenic substrate, in such a manner as to produce a chemical moiety that can be detected, for example, by spectrophotometric, fluorimetric, or by visual means.
- Enzymes that can be used to detectable label the antibody include, but are not limited to, horseradish peroxidase and alkaline phosphatase. The detection can also be accomplished by colorimetric methods that employ a chromogenic substrate for the enzyme.
- Hcy-TTR antibodies may also be accomplished using a variety of other methods.
- a radioimmunoassay RIA
- the radioactive isotope can be detected by such means as the use of a gamma counter or a scintillation counter or by autoradiography .
- the antibody may also be labeled with a fluorescent compound.
- fluorescent labeling compounds are fluorescein isothiocyanate rhodamine, phycoerythrin and fluorescamine.
- a bioluminescent compound may be used to label the Hcy-TTR antibody. The presence of a bio luminescence protein is determined by detecting the presence of luminescence. Important bioluminescence compounds for purposes of labeling are luciferin, luciferase and aequorin.
- Expression levels of Hcy-TTR in biological samples can be analyzed by one or two- dimensional gel electrophoresis.
- Methods of two-dimensional electrophoresis are known to those skilled in the art.
- Two dimensional gel electrophonesis combines separatron by charge and separation by molecular weight.
- Biological samples such as serum samples, are loaded onto electrophoretic gels for isoelectric focusing separation in the first dimension which separates proteins based on charge.
- a number of first-dimension gel preparations may be utilized including tube gels for carrier ampholytes-based separations or gels strips for immobilized gradients based separations.
- proteins are transferred onto the second dimension gel, following an equilibration procedure and separated using SDS PAGE which separates the proteins based on molecular weight.
- SDS PAGE SDS PAGE which separates the proteins based on molecular weight.
- the proteins are transferred from the two dimensional gels onto membranes commonly used for Western blotting.
- the techniques of Western blotting and subsequent visualization of proteins are also well known in the art (Sambrook et al,"Molecular Cloning, A Laboratory Manual", 2 nd Edition, Volume 3,1989, Cold Spring Harbor).
- the standard procedures may be used, or the procedures may be modified as known in the art for identification of proteins of particular types, such as highly basic or acidic, or lipid soluble, etc. (See for example, Ausubel, et al., 1989, Current Protocols in Molecular Biology, Green Publishing Associates and Wiley Interscience, N. Y.).
- Antibodies that bind to the Hcy-TTR are utilized in an incubation step, as in the procedure of Western blot analysis.
- a second antibody specific for the first antibody is often utilized in the procedure of Western blot analysis to visualize proteins that reacted with the first antibody.
- Hcy-TTR can be used as a marker in the clinical diagnosis of hyperhomocysteinemia.
- the market for homocysteine assays is rapidly expanding.
- Hcy-TTR has been an excellent marker for hyperhomocysteinemia. It is particularly useful as a diagnostic or assay in human plasma.
- a practical clinical diagnostic assay will now be developed.
- An immuno-based assay will be ideally suited for clinical diagnosis.
- a monoclonal antibody against Hcy-TTR can be used in any number of settings including ELISA and Abbott Laboratories' IMx platform, which uses fluorescence polarization immunoassay technology.
- 35 S-L-Homocysteine thiolactone was synthesized from 35 S-L- methionine by a slight modification of the method of Hatch et al. (1961) J. Biol. Chem. 236, 1095-1101 and purified as previously described (Sengupta, S. et al., (2001) J. Biol. Chem. 276, 30111-30117 and Sengupta, S. et al, (2001) J. Biol. Chem. 276, 46896-46904 inco ⁇ orated herein by reference).
- 35 S-L-Homocysteine was prepared from 35 S-L-homocysteine thiolactone.
- the thiol content of each preparation of L-homocysteine was determined by the method of Ellman (Ellman, G. L. (1959) Arch. Biochem. Biophys. 82, 70-77). All experiments were conducted with fresh preparations of L-homocysteine and 35 S-L-homocysteine.
- Purified TTR was obtained from Sigma. Human plasma was obtained from healthy donors, subjects with chronic renal failure, and subjects with homocystinuria using approved protocols.
- Radiolabeling and SDS-PAGE of human plasma and purified transthyretin 35 S-L- Homocysteine was incubated with 50% human plasma in 0.05 M TES buffer (pH 7.4), or with purified human transthyretin (1 mg/ml in water) for 5 h at 37 C. Protein was then precipitated with 1.5 M perchloric acid and washed three times with 1.5 M perchloric acid. The final pellet was solubilized in SDS-PAGE sample buffer with and without reduction by ⁇ -mercaptoethanol. After treatment at 100 C for 10 min, aliquots were subjected to analysis by SDS-PAGE using a 10 % gel. The gel was stained with Coomassie blue, dried and subjected to phosphorimaging to detect 35 S- labeled proteins.
- TTR Immunoprecipitation of transthyretin from human plasma.
- TTR was immunoprecipitated from human plasma as described previously in Theberge et al. (1999) Anal. Chem. 71, 452-459. Briefly, 100 ⁇ L of plasma was treated with 80 ⁇ L of goat anti-human transthyretin antiserum (Diasorin, Stillwater, MN) for 12 h at 37 C. The mixture was centrifuged at 14,000 RPM at room temperature for 20 min. After removal of the supernatant, the pellet was washed with 100 ⁇ L of water three times and then dried in a Speed Vac concentrator. The TTR-antibody immunoprecipitate pellets were stored at -70 C until ready for purification by HPLC.
- TTR- antibody immunoprecipitate pellets were thawed and dissolved in water-acetonitrile-acetic acid (80:10:10 v/v/v) and passed through a Millipore Microcon YM-100 centrifugal filter (100,000 molecular weight cutoff) to remove the antibody.
- the filtrate was then applied to an analytical Vydac C-4 HPLC column (25 x 0.46 cm, 5 ⁇ m particle size) and eluted at 0.75 mL/min over 30 min using a gradient of 40-85%> acetonitrile. TTR-related components eluted between 52-54%) acetonitrile.
- the solvent mixture was removed from the protein using a Speed Vac concentrator.
- this instrument was capable of achieving approximately 10 ppm mass accuracy with a minimum resolution of 9000 (full with half maximum).
- 3 ⁇ L of a 1 ⁇ M solution of TTR in methanol-water-formic acid (50:50:1 v/v/v) was loaded into a nanospray needle.
- a stainless steel wire (type 304V, 0.127 mm, 30 gauge; Small Parts, Inc.) was inserted into the nanospray needle containing the sample solution.
- the capillary potential was increased slowly from 0 up to 1.2 kV until a stable ion current was observed.
- the declustering potential was held at 35 V.
- the gel was strained with Coomassie blue, dried and subjected to phosphorimaging to detect 35 S-labeled proteins.
- the objective of this study was to determine if TTR in human plasma reacts with homocysteine under in vitro conditions and if endogenous homocysteinylated TTR is present in normal and hyperhomocysteinemic plasma.
- Human plasma from healthy donors and purified TTR were incubated with 35 S-L-homocysteine for 5 h at 37 C.
- the samples, before and after treatment with ⁇ -mercaptoethanol, were subjected to SDS-PAGE and phosphorimaging. As shown in Fig.
- Binding of Homocysteine and Cysteine to Plasma Proteins and to Purified Fibronectin 35 S-L-homocysteine (500 ⁇ mol/L final concentration) was added to either human plasma fibronectin (1 mg/mL, 0.05 mol/L TES buffer, pH 7.4) or human plasma diluted 1:1 with 0.05 mol/L TES buffer, pH 7.4 and incubated under aerobic conditions for 5 hours at 37°C with continuous shaking.
- SDS-PAGE Samples were combined with SDS-PAGE sample buffer (62.5 mmol/L Tris- HC1, pH 6.8, 2% SDS, 10% glycerol, 0.02% bromophenol blue) and aliquots of some samples were reduced with 2-mercaptoethanol and heated to 100°C for 5 minutes.
- the samples were loaded onto 4-20%> precast gradient gels (Z Axis, Hudson, OH) and electrophoresed using the method of Laemmli. Gels were fixed in 50% methanol, 10% acetic acid, stained with Coomassie blue (Gradipure, Pyrmont, Australia), destained with water, dried, and subjected to phosphorimaging.
- the digested fibronectin was subjected to SDS-PAGE under nonreducing conditions employing a 4-20% precast gradient gel.
- the gel was stained with Coomassie blue, dried, and subjected to phosphorimage analysis to identify radiolabeled peptides.
- a Finnigan LCQ-Deca ion trap mass spectrometer system with a Protana microelectrospray ion source interfaced to a self-packed Phenomenex Jupiter C18 reverse phase capillary chromatography column eluted at a flow rate of 0.2 ⁇ L/min was used. Peptides were eluted from the column with an acetonitrile/0.05 mol/L acetic acid gradient. Full scan mass spectra were obtained to determine molecular mass of the eluting peptides and product ion spectra were recorded to determine amino acid sequence. Peptides were identified by comparing the peptide sequences obtained to those found in the SwissProt and NCBI databases using the FASTA and SEQUEST database search programs. Amino acid residues are numbered as in SwissProt 2.7.2001, accession number P02751.
- Fibronectin Binding to Fibrin A direct binding assay described by Williams et al. 30 was employed to quantify fibronectin binding to fibrin.
- Human fibrinogen (a generous gift from P. M. DiBello, Cleveland Clinic Foundation) in 0.5 mol/L Tris, 0.1 mol/L NaCl, pH 7.6, was added to 96-well Immulon-2 plates (Dynex Technology, Chantilly, VA) at 200 ng/well in a total volume of 100 ⁇ L and dried to the surface by incubation at 37°C for 24 hours.
- Cell Adhesion Assay Cell adhesion was assayed using a method based on those described by Woods et al. and Meighen et al. Control fibronectin, or fibronectin with bound homocysteine was diluted in 0.1 mol/L Tris, pH 9.1 and 1.4 ⁇ g per well was added to Immulon II 96 well plates. The plates were incubated overnight at 4°C. The wells were washed with PBS, blocked with 4%o BSA in PBS for 1 hour at 37°C and rinsed with PBS prior to the addition of cells. Control wells contained only the BSA, and no fibronectin.
- SMCs Rabbit aortic smooth muscle cells (SMCs) were cultured in DME/F12 with Hepes buffer (Gibco BRL, Grand Island, NY) that contained 10% fetal bovine serum (BioWhittaker, Walkersville, MD), and an antibiotic/antimycotic (Gibco BRL) as described.
- the SMCs were incubated in complete medium containing 25 ⁇ g/mL cycloheximide for 2 hours at 37°C prior to the assay.
- the cells were harvested with 5.0 mmol/L EDTA in PBS, rinsed in serum free medium containing 25 ⁇ g/mL cycloheximide, resuspended in serum-free medium with 25 ⁇ g/mL cycloheximide, and plated at a density of 10 5 SMCs per well.
- the plates were incubated at 37°C for 1 hour, and washed with serum-free medium. Attached cells were fixed in 10%) formalin, washed with water, and stained for 30 minutes with 0.2% crystal violet in 80%> methanol.
- the wells were washed with water, the stain was solubilized with 0.1 mol/L sodium citrate, pH 4.2, and absorbance at 590 nm was measured.
- homocysteine to fibronectin increased with increasing homocysteine concentration. In the presence of 500 ⁇ mol/L homocysteine, the binding of homocysteine to fibronectin reached equilibrium within 5 hours. A maximum of 5 moles of homocysteine were bound per mole of dimeric fibronectin.
- the 30 kDa band contained 10 peptides. Eight of these peptides were from the C- terminal region, between residues 2150 and 2356, within and adjacent to the fibrin binding domain, and near a free cysteine sulfhydryl group. The remaining 2 peptides were from the N- terminus and contained amino acids 58-67 and 133-140, which are located in the N-terminal fibrin binding domain. The 34/35 kDa doublet contained 17 fibronectin peptides. The eleven most abundant peptides were again located between amino acids 2150 and 2356, within and adjacent to the fibrin binding domain. Five peptides containing 65 amino acids were from residues 1822 to 1910.
- the last peptide was significantly less abundant and again contained residues 58-67 from the N-terminus.
- the 50 kDa fragment was present in both the undigested, and the digested fibronectin, and contained 7 fibronectin peptides containing 97 amino acids from near the C-terminus. These peptides represented residues 1286-1301, 1788-1796, 1867- 1910, and 2150-2176. Also present in this digest were peptides from bovine serum albumin, a protein known to bind homocysteine, and a contaminant in the commercial fibronectin preparation employed in this experiment.
- LC/MS sequence analysis detected and characterized a relatively extensive series of peptides in each of the three radiolabeled bands. The majority of these peptides were mapped to the C-terminus of the protein sequence, within and adjacent to the C-terminal fibrin-binding domain. This region of the protein also contains a free cysteine residue that may be capable of binding homocysteine. Of the additional peptides that were detected in each of these analyses, several peptides in the 50 kDa band were mapped to albumin, a contaminant in the commercial fibronectin preparation that was used, and a protein known to bind homocysteine.
- the presence of these additional peptides is most likely due to co-migration in the nonreducing SDS-PAGE separation of the limited proteo lysis products.
- the pattern of peptides that were detected in these radiolabeled bands clearly supports the C-terminal region of the fibronectin sequence as a major homocysteine binding domain. Additional experiments were carried out to test the significance of homocysteine binding in this region.
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Physics & Mathematics (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Bioinformatics & Computational Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2002318396A AU2002318396A1 (en) | 2001-06-21 | 2002-06-21 | Homocysteinylated transthyretin |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US29995601P | 2001-06-21 | 2001-06-21 | |
US60/299,956 | 2001-06-21 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2003001182A2 true WO2003001182A2 (fr) | 2003-01-03 |
WO2003001182A3 WO2003001182A3 (fr) | 2005-04-21 |
Family
ID=23157044
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2002/019928 WO2003001182A2 (fr) | 2001-06-21 | 2002-06-21 | Transthyretine homocysteinylee |
Country Status (3)
Country | Link |
---|---|
US (1) | US20030124616A1 (fr) |
AU (1) | AU2002318396A1 (fr) |
WO (1) | WO2003001182A2 (fr) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE102004046840A1 (de) * | 2004-09-27 | 2006-04-06 | Forschungszentrum Karlsruhe Gmbh | Applikationsvorrichtung für Kompressionsmanschetten |
CN108624660A (zh) * | 2018-02-08 | 2018-10-09 | 新开源云扬(广州)医疗科技有限公司 | 一种Hcy代谢关键酶的快速检测试剂盒及检测方法 |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040175754A1 (en) * | 2002-10-09 | 2004-09-09 | David Bar-Or | Diagnosis and monitoring of inflammation, ischemia and appendicitis |
WO2006094185A2 (fr) * | 2005-03-03 | 2006-09-08 | Dmi Biosciences Inc. | Quantification de proteines |
JP2007170992A (ja) * | 2005-12-22 | 2007-07-05 | Abbott Japan Co Ltd | ホモシステインの免疫学的測定方法 |
US20070259376A1 (en) * | 2005-12-22 | 2007-11-08 | Toru Yoshimura | Homocysteine immunoassay |
CN103937793B (zh) | 2008-10-20 | 2017-08-11 | 阿尔尼拉姆医药品有限公司 | 抑制运甲状腺素蛋白表达的组合物和方法 |
WO2011152339A1 (fr) * | 2010-05-31 | 2011-12-08 | Tanaka Noriaki | Méthode permettant de déterminer le stade d'une maladie rénale chronique, dispositif afférent, et son procédé de fonctionnement |
RS60414B1 (sr) | 2011-11-18 | 2020-07-31 | Alnylam Pharmaceuticals Inc | Agensi rnki, kompozicije i postupci za njihovu primenu u lečenju bolesti povezanih sa transtiretinom (ttr) |
US20140315231A1 (en) * | 2011-11-18 | 2014-10-23 | Alnylam Pharmaceuticals, Inc | Quantification of transthyretin and its isoforms |
HUE051998T2 (hu) | 2015-07-31 | 2021-04-28 | Alnylam Pharmaceuticals Inc | Transztiretin (TTR) iRNS készítmények és eljárások azok alkalmazása TTR-asszociált betegségek kezelésére vagy megelõzésére |
JP2021508333A (ja) | 2017-09-19 | 2021-03-04 | アルナイラム ファーマシューティカルズ, インコーポレイテッドAlnylam Pharmaceuticals, Inc. | トランスサイレチン(ttr)媒介アミロイドーシスの治療用組成物及び方法 |
CN117795074A (zh) | 2021-08-03 | 2024-03-29 | 阿尔尼拉姆医药品有限公司 | 转甲状腺素蛋白(TTR)iRNA组合物和其使用方法 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4255443A (en) * | 1979-11-16 | 1981-03-10 | The United States Of America As Represented By The Department Of Health, Education And Welfare | Homocysteine thiolactone perchlorate as a tumor promotor |
US4540573A (en) * | 1983-07-14 | 1985-09-10 | New York Blood Center, Inc. | Undenatured virus-free biologically active protein derivatives |
US4940658A (en) * | 1986-11-20 | 1990-07-10 | University Patents, Inc. | Assay for sulfhydryl amino acids and methods for detecting and distinguishing cobalamin and folic acid deficency |
US5478729A (en) * | 1994-04-28 | 1995-12-26 | Syntex (U.S.A.) Inc. | Immunoassay for homocysteine |
US5817461A (en) * | 1996-01-03 | 1998-10-06 | Hamilton Civic Hospitals Research Development Inc. | Methods and compositions for diagnosis of hyperhomocysteinemia |
US6589751B2 (en) * | 1997-11-04 | 2003-07-08 | Mcw Research Foundation | Immonological detection of the homocystamide adduct and a thiolactone immunoassay for endogeneous homocysteine |
US6174696B1 (en) * | 1999-11-12 | 2001-01-16 | Genzyme Corporation | Method for the determination of homocysteine |
-
2002
- 2002-06-21 AU AU2002318396A patent/AU2002318396A1/en not_active Abandoned
- 2002-06-21 US US10/177,807 patent/US20030124616A1/en not_active Abandoned
- 2002-06-21 WO PCT/US2002/019928 patent/WO2003001182A2/fr not_active Application Discontinuation
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE102004046840A1 (de) * | 2004-09-27 | 2006-04-06 | Forschungszentrum Karlsruhe Gmbh | Applikationsvorrichtung für Kompressionsmanschetten |
CN108624660A (zh) * | 2018-02-08 | 2018-10-09 | 新开源云扬(广州)医疗科技有限公司 | 一种Hcy代谢关键酶的快速检测试剂盒及检测方法 |
Also Published As
Publication number | Publication date |
---|---|
AU2002318396A1 (en) | 2003-01-08 |
WO2003001182A3 (fr) | 2005-04-21 |
US20030124616A1 (en) | 2003-07-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US4900662A (en) | CK-MM myocardial infarction immunoassay | |
Cheung et al. | Immunoassay of a tartrate-resistant acid phosphatase in serum | |
JP2005510234A (ja) | ポリペプチドの定量 | |
US5382515A (en) | Creative kinase-MB immunoassay for myocardial infarction and reagents | |
US20030124616A1 (en) | Homocysteinylated transthyretin | |
US10145853B2 (en) | Biomarkers for non-alcoholic fatty liver disease, and methods for detecting non-alcoholic fatty liver disease by using such biomarkers | |
US4722890A (en) | Quantitative assay for human terminal complement cascade activation | |
JP2517187B2 (ja) | アナライト変異体分析 | |
FI109204B (fi) | Immuunimäärityksiä ja monoklonaalisia vasta-aineita protrombiiniaktivaatiopeptideille ja niiden hajoamistuotteille | |
US20120129187A1 (en) | Diagnostical use of peroxiredoxin 4 | |
US20110039353A1 (en) | Method for direct detection of ischemia-modified albumin using a partner for binding to an aldehyde derivative resulting from the peroxidation of lipids in bound form | |
FI104857B (fi) | Sydänlihaksen soluvaurioiden asteen mittaus immunokemiallisella menetelmällä sisältäen menetelmään soveliaat vasta-aineet | |
JP4164804B2 (ja) | 酒石酸抵抗性酸性ホスファターゼ5bに特異的なモノクローナル抗体およびその用途 | |
JP4903585B2 (ja) | 急性冠症候群用に改善された診断方法 | |
US10175250B2 (en) | Nitrated cardiac troponin I as a biomarker of cardiac ischemia | |
Hoshiyama et al. | Identification of plasma binding proteins for glucose-dependent insulinotropic polypeptide | |
KR20100060897A (ko) | 에틸벤젠 독성 중독 진단용 바이오마커 | |
US4820635A (en) | Kit for assaying activation of terminal complement cascade | |
KR101225846B1 (ko) | 인간 오로트산 포스포리보실 트랜스퍼라아제 단백질의측정법 | |
US5312900A (en) | 23K protein with binding specificity for queuine | |
Fujiwara et al. | Determination of urinary acetylpolyamines by a monoclonal antibody-based enzyme-linked immunosorbent assay (ELISA) | |
Vengerov et al. | Immunochemical studies of human placental alkaline phosphatase in normal and neoplastic tissues | |
WO2023068249A1 (fr) | Réactif de mesure pour n-télopeptide réticulé de collagène de type i, son procédé de préparation et procédé de dosage immunologique l'utilisant | |
KR100882231B1 (ko) | 유방암 진단용 단백질 마커 플라빈 환원효소 및 이에 대한항체를 포함하는 유방암 진단키트 | |
Saile et al. | Quantification of serum amyloid P by enzyme-linked immunosorbent assay |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/2004/000062 Country of ref document: MX |
|
ENP | Entry into the national phase |
Ref document number: 2004103470 Country of ref document: RU Kind code of ref document: A |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
122 | Ep: pct application non-entry in european phase | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
NENP | Non-entry into the national phase |
Ref country code: JP |
|
WWW | Wipo information: withdrawn in national office |
Country of ref document: JP |